Peripal AG was founded by ETH and industry experts and has closed a seed round previously. It has now executed its 1st Closing of a Series A financing round to advance product develop-ment and launch the product(s). Among its new investors are the StartAngels Network (SAN), Zürich, (with E. Platzer as Lead Investor), as well as Zürcher Kantonalbank and Aargauische Kantonalbank. “We expect our Peripal System® to facilitate the therapy process and to shorten training times. By making home dialysis easier and safer for patients, we also help to reduce healthcare costs”, says Dr. Sandra Neumann, founder and CEO of Peripal AG.
Peripal AG’s product addresses a key step in home dialysis: the manual connection of dialysis tubings to patients’ catheters. This handling by patients/relatives requires dexterity and car-ries the risk of infection, thereby posing a critical hurdle to home dialysis. Each day, more than 1 million such connections are performed worldwide.
“With the Series A financing, for which there may be a second close in May, we will further invest into the industrialization and expand the team”, says Reto Koch, chairman of the board.
Chronic kidney failure increases at a rate of 2-4% annually, driven by age, diabetes, and hy-pertension. With the support of Peripal AG’s patient aid device, more patients can receive their therapy in a home setting as opposed to the hospital, resulting in considerable healthcare cost reductions and, hopefully, improved quality of life.
For more information please visit: www.peripal.com
About Peripal AG
Peripal AG is an ETH start-up developing medical devices to facilitate dialysis.
There exist about 3 million dialysis patients worldwide and about 300’000 of these perform their dialysis at home with the so-called peritoneal dialysis. Each one of these patients needs to manually connect a catheter to a dialysis product several times a day. Peripal AG’s patient aid supports such a connection.
Peripal AG is based in Zurich. It develops and commercializes a novel patient aid for chronic dialysis patients at home. Its vision is to allow more dialysis patients to be treated at home.
Contact
info@peripal.com, Dr. Sandra Neumann CEO / Founder
Peripal AG’s product addresses a key step in home dialysis: the manual connection of dialysis tubings to patients’ catheters. This handling by patients/relatives requires dexterity and car-ries the risk of infection, thereby posing a critical hurdle to home dialysis. Each day, more than 1 million such connections are performed worldwide.
“With the Series A financing, for which there may be a second close in May, we will further invest into the industrialization and expand the team”, says Reto Koch, chairman of the board.
Chronic kidney failure increases at a rate of 2-4% annually, driven by age, diabetes, and hy-pertension. With the support of Peripal AG’s patient aid device, more patients can receive their therapy in a home setting as opposed to the hospital, resulting in considerable healthcare cost reductions and, hopefully, improved quality of life.
For more information please visit: www.peripal.com
About Peripal AG
Peripal AG is an ETH start-up developing medical devices to facilitate dialysis.
There exist about 3 million dialysis patients worldwide and about 300’000 of these perform their dialysis at home with the so-called peritoneal dialysis. Each one of these patients needs to manually connect a catheter to a dialysis product several times a day. Peripal AG’s patient aid supports such a connection.
Peripal AG is based in Zurich. It develops and commercializes a novel patient aid for chronic dialysis patients at home. Its vision is to allow more dialysis patients to be treated at home.
Contact
info@peripal.com, Dr. Sandra Neumann CEO / Founder
